Abstract
This population-based study evaluates the short-term risk of severe cardiovascular events among French residents aged 75 years or older after receipt of the BNT162b2 mRNA COVID-19 vaccination.
MeSH terms
-
Age Factors
-
Aged
-
Aged, 80 and over
-
BNT162 Vaccine / adverse effects*
-
COVID-19 / prevention & control
-
Databases, Factual
-
France / epidemiology
-
Humans
-
Incidence
-
Myocardial Infarction / epidemiology
-
Myocardial Infarction / etiology*
-
Pulmonary Embolism / epidemiology
-
Pulmonary Embolism / etiology*
-
Risk
-
Stroke / epidemiology
-
Stroke / etiology*